Glass House Brands has submitted applications to register certain California-licensed medical cannabis operations with the U.S. Drug Enforcement Administration (DEA) pursuant to the expedited registration pathway established by the recent rescheduling of medical cannabis to Schedule III under the Controlled Substances Act.
In connection with the Schedule III reclassification of medical cannabis, the DEA established an expedited registration process for eligible state-licensed medical marijuana operators. Medical cannabis dispensaries that register with the DEA during the 60-day window may operate under Schedule III while the DEA processes those applications.
© Glass House Brands
The Company will discuss the rescheduling of medical cannabis as well as recent financial results on its first quarter investor call scheduled for Wednesday, May 13, 2026 at 5:00 p.m. Eastern Time.
For more information:
Glass House Brands
[email protected]
glasshousebrands.com/
